Proteome Markers for Alzheimer's Disease Diagnosis

用于阿尔茨海默病诊断的蛋白质组标记

• 批准号: 6721495
• 负责人: KELVIN H LEE
• 金额: $ 23.92万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6721495
• 关键词: Alzheimer' s disease; biomarker; cerebrospinal fluid; electrophoresis; human subject; mental disorder diagnosis; proteins

DESCRIPTION (Adapted from applicant's abstract): The objective of this project is to identify CSF molecular markers associated with the antemortem diagnosis of Alzheimer's disease which can be used as a measure for disease pathology. In contrast to brain based studies of the molecular mechanism of disease progression, this investigation with use proteomics technology to identify and characterize CSF proteins of interest. This information can be used to categorize disease pathology or can be used to develop immunoassays for diagnosis. In order to achieve these long-term objectives, the investigator plans to: identify and obtain CSF blood samples and clinical information from an appropriate sample population of patients with different forms of dementia, probable Alzheimer's disease at various stages and controls (Specific Aim 1). Analyze the samples for AD specific protein markers used in proteome analysis that includes high solution two-dimensional electrophoresis, laser densitometry, fluorescence imaging, and computer aided in each analysis (Specific Aim 2). He employs multivariate statistics to establish a correlation between relevant changes in disease diagnosis and establish qualitative and quantitative bar code for diagnosis of Alzheimer's disease. This includes the validation of other proposed CSF markers such as tau and Abeta 42 as well as the preliminary identification of other major differential diagnosis such as vascular dementia, dementia with Lewy bodies (Specific Aim 3). Use microchemical characterization of important proteins to elucidate the genetic basis of the molecular markers and other reference proteins. This information can also be used to develop immunoassays (Specific Aim 4).

描述（改编自申请人摘要）：本项目的目标 是确定与死前诊断相关的脑脊液分子标记 它可以作为疾病病理学的一个指标。在 与基于大脑的疾病分子机制研究相比， 本研究利用蛋白质组学技术， 表征感兴趣的CSF蛋白。该信息可用于 分类疾病病理或可用于开发免疫测定， 诊断.为了实现这些长期目标，研究人员 计划：识别并获得CSF血样和临床信息， 一个合适的不同形式的痴呆症患者样本群体， 可能的阿尔茨海默病在不同阶段和控制（具体目标1）。 分析样品中用于蛋白质组分析的AD特异性蛋白质标记物 包括高分辨率双向电泳，激光 密度测定法、荧光成像法和计算机辅助分析 （具体目标2）。他运用多元统计学建立了一个相关性 在疾病诊断的相关变化和建立定性和 用于诊断阿尔茨海默病的定量条形码。这包括 验证其他提出的CSF标志物，如tau和Abeta 42以及 其他主要鉴别诊断初步鉴定，如 血管性痴呆、路易体痴呆（具体目标3）。使用 重要蛋白质的微化学表征，以阐明遗传 分子标记和其他参考蛋白的基础。这些信息 也可用于开发免疫测定（特定目标4）。

项目成果

Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approach.

阿尔茨海默病脑脊液生物标志物的发现：蛋白质组学方法。

• 发表时间: 2005
• 期刊: Current opinion in molecular therapeutics.
• 作者: D'Ascenzo,Mark;Relkin,NormanR;Lee,KelvinH
• 通讯作者: Lee,KelvinH

Two-dimensional protein electrophoresis: from molecular pathway discovery to biomarker discovery in neurological disorders.

二维蛋白质电泳：从分子途径发现到神经系统疾病生物标志物发现。

• DOI: 10.1016/j.nurx.2006.05.001
• 发表时间: 2006
• 期刊: NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
• 作者: Choe,LeilaH;Werner,BrendaG;Lee,KelvinH
• 通讯作者: Lee,KelvinH

Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease.

• DOI: 10.1155/2005/806573
• 发表时间: 2005
• 期刊: Disease markers
• 作者: Finehout EJ;Franck Z;Lee KH
• 通讯作者: Lee KH